Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2003
Published online before print May 22, 2003, doi: 10.1161/01.RES.0000078172.52740.9B
A more recent version of this article appeared on June 27, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/12/1285    most recent
01.RES.0000078172.52740.9Bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dewberry, R. M.
Right arrow Articles by Francis, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dewberry, R. M.
Right arrow Articles by Francis, S. E.

Submitted on March 5, 2003
Revised on May 9, 2003
Accepted on May 9, 2003

Interleukin-1 Receptor Antagonist (IL-1RN) Genotype Modulates the Replicative Capacity of Human Endothelial Cells

Rachael M. Dewberry ; David C. Crossman ; and Sheila E. Francis *

From the Cardiovascular Research Group, Clinical Sciences (North), University of Sheffield, Northern General Hospital, Sheffield, UK.

* To whom correspondence should be addressed. E-mail: s.francis{at}sheffield.ac.uk.

Endothelial cells (ECs) undergo a finite number of cell divisions before growth arrest or replicative senescence; this is modulated in part by the proinflammatory cytokine, interleukin-1 (IL-1). IL-1 and its family members are expressed in human atherosclerotic vessels, mainly in the endothelium. EC replicative senescence and IL-1 have been associated with atherosclerosis. Genetic variants at the IL-1 locus have been associated with a variety of coronary phenotypes. In this study, we examined the relationship between the interleukin-1 receptor antagonist variable number tandem repeat allele 2 (IL-1RN*2*2) and EC replicative capacity. A significant decrease in EC cumulative population doublings (CPDs) was associated with the rare allele (IL-1RN*2*2) at IL-1RN, 8.56±0.97 (n=7) versus 13.14±1.00 (IL-1RN*1*1, n=20), P=0.0118. Proliferation of IL-1RN*2*2 ECs detected by Ki67 expression was also significantly reduced particularly at later passage, passage 6: 21.76±0.93% (n=6) versus 48.10±8.81% (IL-1RN*1*1, n=7) (P=0.0323) and passage 8: 22.48±3.08% (n=6) versus 42.29±3.06% (IL-1RN*1*1, n=7) (P=0.0028). IL-1RN*2 carriage was associated with increased numbers of senescent ECs detected by senescence-associated {beta}-galactosidase staining. Basal apoptosis, telomerase activity, and telomere length were not different with respect to IL-1RN genotype. Addition of exogenous IL-1ra (1 ng/mL) increased CPDs in a number of human umbilical vein endothelial cell cultures and increased proliferating cells from 12.11±1.21% to 27.82±2.82% (P=0.0216) with IL-1RN*2*2 at passage 8 (n=2). These data suggest genetic control of EC proliferation and life span by the IL-1 locus and imply that IL-1ra may have a function connected with EC growth.


Key words: interleukin-1 receptor antagonist • endothelial cells • proliferation




This article has been cited by other articles:


Home page
StrokeHome page
B. B. Worrall, T. G. Brott, R. D. Brown Jr, W. M. Brown, S. S. Rich, S. Arepalli, F. Wavrant-De Vrieze, J. Duckworth, A. B. Singleton, J. Hardy, et al.
IL1RN VNTR Polymorphism in Ischemic Stroke: Analysis in 3 Populations
Stroke, April 1, 2007; 38(4): 1189 - 1196.
[Abstract] [Full Text] [PDF]